Literature DB >> 19843243

Dormancy of metastatic melanoma.

Liliana Ossowski1, Julio A Aguirre-Ghiso.   

Abstract

Metastatic dormancy of melanoma has not received sufficient attention, most likely because once detectable, metastasis is almost invariably fatal and, understandably, the focus has been on finding ways to prolong life of patients with overt recurrences. Nevertheless, analysis of the published clinical and experimental data on melanoma indicates that some aspect of melanoma biology imitate traits recently associated with dormancy in other solid cancers. Among them the ability of some melanomas to disseminate early during primary tumor progression and once disseminated, to remain undetected (dormant) for years. Comparison of cutaneous and uveal melanoma indicates that, in spite of being of the same origin, they differ profoundly in their clinical progression. Importantly for this discussion, between 40 and 50% of uveal melanoma remain undetected for longer than a decade, while less than 5% of cutaneous melanoma show this behavior. Both types of melanoma have activating oncogene mutations that provide autonomous pro-proliferative signals, yet the consensus is that those are not sufficient for tumor progression. If that is the case, it is possible to envision that signals from outside the tumor cell, (microenvironment) shape the fate of an individual disseminated cell, regardless of an oncogene mutation, to progress or to pause in a state of dormancy. To stimulate further debate and inquiry we describe here a few examples of potential signals that might modify the fate of disseminated cell and provide brief description of the current knowledge on dormancy in other cancers. Our hope is to convince the reader that disseminated melanoma cells do enter periods of prolonged dormancy and that finding ways to induce it, or to prolong it, might mean an extension of symptoms-free life for melanoma patients. Ultimately, understanding the biology of dormancy and the mechanisms of dormant cell survival, might allow for their specific targeting and elimination.

Entities:  

Mesh:

Year:  2009        PMID: 19843243      PMCID: PMC2821074          DOI: 10.1111/j.1755-148X.2009.00647.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  162 in total

1.  The distribution of secondary growths in cancer of the breast. 1889.

Authors:  S Paget
Journal:  Cancer Metastasis Rev       Date:  1989-08       Impact factor: 9.264

Review 2.  Stem cells in melanoma development.

Authors:  Marianna Sabatino; David F Stroncek; Harvey Klein; Francesco M Marincola; Ena Wang
Journal:  Cancer Lett       Date:  2008-12-17       Impact factor: 8.679

3.  Melanoma vaccines: The problems of local immunosuppression.

Authors:  Marta E Polak; Nicola J Borthwick; Martine J Jager; Ian A Cree
Journal:  Hum Immunol       Date:  2009-05       Impact factor: 2.850

Review 4.  Cancer micrometastases.

Authors:  Klaus Pantel; Catherine Alix-Panabières; Sabine Riethdorf
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

5.  Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-05       Impact factor: 11.205

6.  Late recurrence of malignant melanoma. Analysis of 168 patients.

Authors:  N J Crowley; H F Seigler
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

Review 7.  BRAF signaling and targeted therapies in melanoma.

Authors:  Nathalie Dhomen; Richard Marais
Journal:  Hematol Oncol Clin North Am       Date:  2009-06       Impact factor: 3.722

8.  Late recurrence of stage I malignant melanoma.

Authors:  M Gutman; J M Klausner; M Inbar; R R Rozin
Journal:  J Surg Oncol       Date:  1989-10       Impact factor: 3.454

9.  Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Authors:  David Dankort; David P Curley; Robert A Cartlidge; Betsy Nelson; Anthony N Karnezis; William E Damsky; Mingjian J You; Ronald A DePinho; Martin McMahon; Marcus Bosenberg
Journal:  Nat Genet       Date:  2009-03-12       Impact factor: 38.330

Review 10.  Number crunching in the cancer stem cell market.

Authors:  Malcolm R Alison; Shahriar Islam; Susan M L Lim
Journal:  Breast Cancer Res       Date:  2009-04-24       Impact factor: 6.466

View more
  47 in total

1.  Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma.

Authors:  Jo Eyles; Anne-Laure Puaux; Xiaojie Wang; Benjamin Toh; Celine Prakash; Michelle Hong; Tze Guan Tan; Lin Zheng; Lai Chun Ong; Yi Jin; Masashi Kato; Armelle Prévost-Blondel; Pierce Chow; Henry Yang; Jean-Pierre Abastado
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

2.  An optimized isolation of biotinylated cell surface proteins reveals novel players in cancer metastasis.

Authors:  Piia-Riitta Karhemo; Suvi Ravela; Marko Laakso; Ilja Ritamo; Olga Tatti; Selina Mäkinen; Steve Goodison; Ulf-Håkan Stenman; Erkki Hölttä; Sampsa Hautaniemi; Leena Valmu; Kaisa Lehti; Pirjo Laakkonen
Journal:  J Proteomics       Date:  2012-07-17       Impact factor: 4.044

Review 3.  ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.

Authors:  Maria Soledad Sosa; Alvaro Avivar-Valderas; Paloma Bragado; Huei-Chi Wen; Julio A Aguirre-Ghiso
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

4.  Breast and other cancer dormancy as a therapeutic endpoint: speculative recombinant T cell receptor ligand (RTL) adjuvant therapy worth considering?

Authors:  Tibor Bakács; Jitendra N Mehrishi
Journal:  BMC Cancer       Date:  2010-06-02       Impact factor: 4.430

5.  Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.

Authors:  Xi Zhao; Anamika Bose; Hideo Komita; Jennifer L Taylor; Nina Chi; Devin B Lowe; Hideho Okada; Ying Cao; Debabrata Mukhopadhyay; Peter A Cohen; Walter J Storkus
Journal:  J Immunol       Date:  2012-01-13       Impact factor: 5.422

6.  Formation of spherical cancer stem-like cell colonies with resistance to chemotherapy drugs in the human malignant fibrous histiocytoma NMFH-1 cell line.

Authors:  Liang Deng; Dejian Li; Wenguang Gu; Aiguo Liu; Xiangyang Cheng
Journal:  Oncol Lett       Date:  2015-09-16       Impact factor: 2.967

Review 7.  Regulation of tumor cell dormancy by tissue microenvironments and autophagy.

Authors:  Maria Soledad Sosa; Paloma Bragado; Jayanta Debnath; Julio A Aguirre-Ghiso
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 8.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

Review 9.  Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

Authors:  Michael Hölzel; Anton Bovier; Thomas Tüting
Journal:  Nat Rev Cancer       Date:  2013-03-28       Impact factor: 60.716

10.  Cancer stem cells in solid tumors: elusive or illusive?

Authors:  Yvonne Welte; James Adjaye; Hans R Lehrach; Christian Ra Regenbrecht
Journal:  Cell Commun Signal       Date:  2010-05-11       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.